Research programme: myocardial infarction gene therapeutics - SmartPharm Therapeutics
Latest Information Update: 28 Oct 2023
At a glance
- Originator SmartPharm Therapeutics
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Parenteral, Injection)
- 01 Sep 2020 SmartPharm Therapeutics has been acquired by Sorrento Therapeutics
- 05 Sep 2019 Preclinical trials in Cardiovascular disorders in USA (IV)